Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Alison DaCostaCharles R Esther

Abstract

Mycobacterium abscessus infection is associated with declining lung function in cystic fibrosis (CF), but there is little evidence on clinical efficacy to guide treatment. Retrospective review of 37 CF patients treated for M. abscessus respiratory infection at a single center from 2006 to 2014. Outcomes included change in FEV1 at 30, 60, 90, 180, and 365days after treatment and clearance of M. abscessus from sputum cultures. Lung function was significantly improved after 30 and 60days of treatment, but not at later time points. Gains were inversely related to starting lung function. Antibiotic choices did not influence outcomes except for greater clearance with clarithromycin. Treatment of M. abscessus resulted in short term improvement in lung function that is inversely related to pre-treatment FEV1.

References

Nov 16, 2002·American Journal of Respiratory and Critical Care Medicine·Kenneth N OlivierUNKNOWN Nontuberculous Mycobacteria in Cystic Fibrosis Study Group
Apr 29, 2005·Pediatric Pulmonology·Charles R EstherMargaret W Leigh
Feb 6, 2007·American Journal of Respiratory and Critical Care Medicine·David E GriffithUNKNOWN Infectious Disease Society of America
Aug 8, 2009·American Journal of Respiratory and Critical Care Medicine·Kyeongman JeonWon-Jung Koh
Jan 15, 2010·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Charles R EstherPeadar G Noone
Sep 14, 2010·American Journal of Respiratory and Critical Care Medicine·Won-Jung KohO Jung Kwon
Feb 4, 2011·Journal of Clinical Microbiology·Charles R EstherPeter Gilligan
Feb 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Julie JarandCharles L Daley
Aug 11, 2012·American Journal of Respiratory and Critical Care Medicine·Go-Eun ChoiWon-Jung Koh
Sep 21, 2013·Current Opinion in Pulmonary Medicine·Janice M Leung, Kenneth N Olivier
Nov 21, 2013·Annals of the American Thoracic Society·Stacey L MartinianoScott D Sagel
Jan 28, 2014·Annals of the American Thoracic Society·Kenneth N OlivierD Rebecca Prevots
Feb 7, 2014·The Journal of Antimicrobial Chemotherapy·Florian P MaurerAkos Somoskövi
Jun 12, 2014·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Ophir Bar-OnHannah Blau
Jul 30, 2014·American Journal of Respiratory and Critical Care Medicine·Jennifer AdjemianD Rebecca Prevots
Dec 4, 2014·The Cochrane Database of Systematic Reviews·Valerie Waters, Felix Ratjen
Feb 14, 2015·Clinics in Chest Medicine·Stacey L Martiniano, Jerry A Nick
Feb 10, 2016·Clinics in Chest Medicine·Stacey L MartinianoCharles L Daley

❮ Previous
Next ❯

Citations

Apr 24, 2019·Antimicrobial Agents and Chemotherapy·Augusto Cesar Hunt-SerracinCara C Boutte
Nov 21, 2018·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Cecilie RavnholtTavs Qvist
Sep 8, 2017·Pediatric Pulmonology·Stacey L MartinianoJerry A Nick
Dec 14, 2018·Frontiers in Microbiology·Christopher VinnardKeith Hamilton
Feb 6, 2021·The European Respiratory Journal·Dominic A HughesSiobhán B Carr
May 30, 2019·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Brandon BanaschewskiThomas Hofmann
Aug 26, 2021·Current Opinion in Pulmonary Medicine·Jerry A NickRebecca M Davidson

❮ Previous
Next ❯

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Related Papers

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Charles R EstherPeadar G Noone
Revista española de quimioterapia : publicación oficial de la Sociedad Española de Quimioterapia
Alexandra Martín-RamírezTeresa Alarcón-Cavero
© 2022 Meta ULC. All rights reserved